Ipamorelin

Ipamorelin is a synthetic pentapeptide belonging to the class of growth hormone secretagogues (GHS) and is characterized in the research literature as one of the more selective ligands at the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). It is supplied as a lyophilized powder for reconstitution and is provided strictly for research and professional laboratory use; it is not approved by the FDA for therapeutic use. Within the Growth Hormone & Performance reference category, it is studied in preclinical and investigational contexts for its reported ability to stimulate endogenous growth hormone release in a pulsatile manner.

In the published literature, Ipamorelin is frequently described in terms of its reported selectivity relative to earlier secretagogues, with research noting minimal observed influence on cortisol and prolactin in the models examined. This entry is intended for licensed-practitioner evaluation only and does not constitute a representation of safety, efficacy, or approval for any clinical indication. Individual results vary, and any findings described reflect published research contexts rather than guaranteed outcomes.

• Investigated in preclinical literature for its role as a selective growth hormone secretagogue and for the study of endogenous, pulsatile growth hormone release
• Studied in research models for its reported interaction with the GHS-R1a (ghrelin) receptor and associated signaling pathways
• Examined in the literature for its reported selectivity relative to other secretagogues, including observations of cortisol and prolactin in the models studied
• Explored in research settings related to growth hormone axis regulation and body composition endpoints; individual results vary
• Referenced in comparative peptide research alongside other growth hormone secretagogues to characterize receptor binding and release kinetics

For research handling reference only: this compound is typically supplied as a lyophilized powder and is generally reconstituted with bacteriostatic water or another sterile diluent appropriate to the laboratory protocol. The diluent is commonly introduced slowly against the inner wall of the vial rather than directly onto the powder, and the vial is gently swirled rather than shaken to support dissolution. Unreconstituted lyophilized vials are commonly stored frozen or refrigerated and protected from light and moisture; once reconstituted, solutions are generally kept refrigerated, protected from light, and handled using aseptic technique. Repeated freeze-thaw cycles and exposure to heat are generally avoided. All research and clinical protocols, including any decisions regarding preparation, concentration, and use, are determined solely by the licensed ordering provider exercising independent professional judgment; this is reference information only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

Ipamorelin is described in the research literature as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor engaged by endogenous ghrelin. Binding at this receptor is reported in studies to stimulate the somatotroph cells of the anterior pituitary to release growth hormone in a pulsatile fashion, through a pathway considered distinct from that of growth hormone-releasing hormone (GHRH). Published preclinical work has noted that this secretagogue activity appears relatively selective in the models studied, with limited observed effect on the release of other pituitary hormones such as cortisol and prolactin. These mechanistic descriptions reflect proposed and studied pathways in research contexts; individual results vary and these are not therapeutic claims.